Skip to main content

Table 1 Demographic and biochemical characteristics of the healthy control group and patient groups

From: Role of nuclear factor kappa B, interleukin-19, interleukin-34, and interleukin-37 expression in diabetic nephropathy

Parameter

H. control

Diabetic

CKD

DCKD

Number of subjects

30

30

50

50

Gender (No)

Male

13

15

27

30

Female

17

15

23

20

Age (Years)

43.10 ± 12.11a

44.67 ± 13.72a

47.54 ± 14.38a

46.96 ± 12.92a

BMI (Kg/m2)

24.46 ± 2.19a

31.38 ± 5.65b

24.98 ± 3.91a

30.67 ± 5.08b

SBP (mmHg)

117.99 ± 7.79a

135.43 ± 12.42b

139.36 ± 16.5b

146.66 ± 19.69c

DBP (mmHg)

80.00 ± 5.29a

88.23 ± 7.44b

93.7 ± 11.28b

91.64 ± 11.16b

FBS (mg/dL)

90.67 ± 8.76a

211.53 ± 44.86c

89.76 ± 9.07a

174.0 ± 47.63b

HbA1c (%)

5.44 ± 0.40a

7.97 ± 1.12b

5.66 ± 0.50a

7.62 ± 1.18b

HOMA-IR

1.93 ± 0.34a

4.36 ± 0.88b

2.33 ± 0.69a

4.47 ± 1.24b

HOMA-IS

13.9 ± 2.80c

5.88 ± 1.38a

11.68 ± 4.11b

6.06 ± 2.17a

HOMA-β

115.16 ± 55.45c

44.83 ± 15.81b

105.36 ± 99.5c

32.01 ± 30.2a

  1. Data are expressed as means ± SD. Values that share the same superscript symbol(s) are not significantly different. H: healthy, CKD: chronic kidney disease, DCKD: diabetic chronic kidney disease. SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, HbA1c: glycosylated hemoglobin, FBS: fasting blood sugar, HOMA-IR: homeostasis model assessment for insulin resistance, HOMA-IS: homeostasis model assessment for insulin sensitivity, HOMA-β: homeostasis model assessment for beta-cell function